Multiplex Apolipoprotein Panel Boosts Cardiovascular Risk Prediction and Precision Therapy
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, posted on LinkedIn:
”New in ATVB (Nov 2025)
Multiplex Apolipoprotein Panel Boosts Cardiovascular Risk Prediction and Precision Therapy
In >11,800 post-ACS patients from ODYSSEY OUTCOMES, a 9-plex mass-spectrometry apolipoprotein panel outperformed the standard lipid profile in predicting:
• Major adverse cardiovascular events (MACE) (AUC 0.65 vs 0.58)
• All-cause death (AUC 0.70 vs 0.60)
The panel also identified which patients benefit most from PCSK9 inhibition (alirocumab) – paving the way for precision lipidology.
Key components: Apo(a), ApoA-I, ApoA-II, ApoA-IV, ApoB, ApoC-I, ApoC-II, ApoC-III, ApoE.
Alirocumab reduced Apo(a), ApoB, and ApoC isoforms by >30–50%.
Bottom line:
Integrated apolipoprotein profiling refines risk stratification and optimizes treatment allocation – a step forward in personalized cardiovascular medicine.
Open Access”
Title: Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy
Authors: Esther Reijnders, Patrick M. Bossuyt, J. Wouter Jukema, L. Renee Ruhaak, Fred P.H.T.M. Romijn, Michael Szarek, Stella Trompet, Deepak L. Bhatt, Vera A. Bittner, Rafael Diaz, Sergio Fazio, Irena Stevanovic, Shaun G. Goodman, Robert A. Harrington, Harvey D. White, Philippe Gabriel Steg, Gregory G. Schwartz, Christa M. Cobb
Stay informed with Hemostasis Today.
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:18Thomas Dayspring: Prognostic Impact of Lp(a) Changes Following Statin Therapy in Patients with CAD
-
Aug 26, 2026, 14:17Khurram Nasir: Are We Debating the Wrong Thing About Research in Medical Training?
-
Aug 26, 2026, 14:15Nathan Connell: Why Format Free Publishing Still Demands Formatting?
-
Aug 26, 2026, 14:14Reza Shojaei: China’s Reliance on Imported Albumin Raises Global Plasma Security Concerns
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM